crenauer

Cory Renauer

Cory is a long-term minded analyst mainly focused on the biotechnology and pharmaceuticals. He genuinely enjoys cutting through the industry's complexities to help everyday investors make better decisions. He's a husband and father that is always up for just about any outdoor activity. You can contact Cory on Twitter @coryrenauer

crenauer’s Activity

Wed Apr 27

NL

Article

crenauer published an article 8:48 PM

This One Drug Alone Makes Celldex Therapeutics, Inc. a Buy (Hint: It's not Rintega)

With over two-thirds of its market cap in cash and marketable securities, one successful candidate could make this stock a winner.

Tue Apr 26

NL

Article

crenauer published an article 3:10 PM

Could a Pill to Cure Alzheimer's Disease Become Available Soon?

After taking an experimental pill developed by Anavex Life Sciences, two women with Alzheimer's have regained their ability to play piano and paint. How soon until it could be available for everyone with the disease?

Wed Apr 20

NL

Article

crenauer published an article 8:14 PM

bluebird bio, Inc. Takes Flight Towards First Approval

...to a resounding "meh" from Wall Street.

Mon Apr 18

NL

Article

crenauer published an article 5:53 PM

Ignore MannKind Corp.: Here Are 3 Better Stocks

MannKind's fragile finances make these clinical-stage biotechs relative safe havens -- with far more exciting potential.

Sun Apr 17

NL

Article

crenauer published an article 3:02 PM

4 Healthcare Stocks That Are Looking Cheap

From big pharmas, to clinical-stage biotechs, to tiny device makers, healthcare bargains are out there.

Sat Apr 16

Caps Pick

crenauer made a pick in CAPS. 11:04 AM

MannKind Corp (MNKD) will Underperform the S&P 500

Fri Apr 15

NL

Article

crenauer published an article 2:21 PM

Better Buy: Exelixis, Inc. vs. Roche

Exelixis has potential for larger gains in the years ahead than Roche, but is it worth the risk?

Wed Apr 13

NL

Article

crenauer published an article 6:25 PM

How Big Is the St. Jude Medical Threat to Abiomed, Inc. Stock?

As a minnow among sharks, Abiomed shares are rightfully volatile. Here's why this Fool expects it to survive and thrive.

Mon Apr 11

NL

Article

crenauer published an article 7:57 PM

Diabetes Drug Shakeup: What You Need to Know About New FDA Warnings

The next generation of type-2 diabetes drugs may get another boost.

Sun Apr 10

NL

Article

crenauer published an article 1:49 PM

Why Seattle Genetics, Inc. Stock Rose 10% in March

Some insider buying from the company's largest shareholders helped this burgeoning pioneer of targeted cancer therapies recover from this year's broad biotech selloff.

Sat Apr 9

NL

Article

crenauer published an article 3:02 PM

Why Kite Pharma, Inc. Stock Dwindled 10% in March

As CAR-T development carries companies deeper into uncharted waters, insignificant ripples become double-digit waves.

Fri Apr 8

NL

Article

crenauer published an article 5:01 PM

Why Vertex Pharmaceuticals Incorporated Stock Dipped 11% in March

European sales growth concerns weighed down the cystic fibrosis leader, but the bouncing is far from over.

Thu Apr 7

NL

Article

crenauer published an article 7:42 PM

Why Raptor Pharmaceuticals Corp. Stock Rose 25% in March

This stock is as prone to soaring (and diving) as its name suggests.

NL

Article

crenauer published an article 2:20 PM

Why Puma Biotechnology, Inc. Stock Crashed 37% in March

Puma's window of opportunity to build a bigger pipeline around neratinib just got a little smaller.

Wed Apr 6

NL

Article

crenauer published an article 4:35 PM

Why Agenus Inc. Stock Soared 43% in March

A glowing fourth-quarter earnings report reminded the market that not all biotechs are cut from the same cloth.

Caps Pick

crenauer made a pick in CAPS. 11:32 AM

Agenus, Inc. (AGEN) will Outperform the S&P 500

Caps Pick

crenauer made a pick in CAPS. 10:51 AM

Celldex Therapeutics (CLDX) will Outperform the S&P 500

Tue Apr 5

NL

Article

crenauer published an article 5:45 PM

Why Celldex Therapeutics, Inc. Stock Sank 50% in March

Rintinga's failure in the company's first phase 3 trial throws Celldex's entire pipeline into question.

Caps Pick

crenauer made a pick in CAPS. 10:26 AM

ANAVEX LIFE SCIENCES (AVXL) will Underperform the S&P 500

Sun Apr 3

NL

Article

crenauer published an article 5:55 PM

Anavex Life Sciences Stock: 1 Key Number You Must Know

It's 100 million. Find out why this figure means everything.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 51.23
Player Rank 36509 out of 74850
Score -1.20
Score Change Today -46.82
Accuracy 49.37%
Active Picks 16
Total Picks 88
Best Pick NPSP.DL (+169.80)
Worst Pick NSPH (-121.59)
Average Score per Pick -0.01
Charms Earned 2
Highest Rated Favorite TMFBiologyFool
Go to crenauer’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show crenauer’s 10 Latest Posts